Inhibition of XXXX in whole blood by @entity167 .

@entity1 @entity1423 @entity167 @entity16447 @entity1426 @entity35 @entity857 @entity1068 @entity2142
Our previous studies have demonstrated that addition of moderate volumes of absolute @entity167 (34-170 mM final concentration) to whole blood produces concentration-dependent @entity1423 , due to release of @entity857 ( @entity857 ) from erythrocytes. We have now investigated the effects of exposure of blood to @entity1068 by a more "physiologic" protocol, in which 7.8% (w/v) @entity167 is added to achieve a final concentration of 1 to 85 mM in @entity1 and @entity35 blood or platelet rich plasma ( @entity16447 ). The effects of short incubation with @entity167 on @entity1423 induced by @entity857 , collagen and @entity1426 were examined by the impedance method of aggregometry. Aggregation induced by collagen in @entity16447 of either species was significantly inhibited by 85 mM @entity1068 , with concentrations as low as 4.25 mM inhibiting the response to collagen in @entity35 whole blood. @entity857 stimulated only primary, reversible aggregation in @entity35 @entity16447 and whole blood, and these responses were unaffected by @entity167 . @entity1 platelets responded to @entity857 with irreversible aggregation, which was significantly attenuated by 85 mM @entity1068 in whole blood but not @entity16447 . @entity1426 evoked irreversible @entity1423 in all four preparations; this was significantly inhibited by the high dose @entity1068 in @entity1 and @entity35 @entity16447 , but not whole blood. In contrast to our earlier studies with absolute @entity1068 , there was no evidence of @entity2142 (and therefore, @entity857 release from red blood cells) using the current protocol. The results of these experiments show that @entity167 , at physiologically relevant concentrations, has an inhibitory effect on secondary @entity1423 responses to some agonists in whole blood as well as @entity16447 , possibly by its previously demonstrated effects on @entity1426 release by phospholipases. The possibility remains to be considered that other blood cells might contribute to the effects of @entity167 on @entity1423 in whole blood.
